GlassScriptPhysician profile
Jennifer Waddle
NPI 1366656787
$2,687.00
in general payments reported to CMS, 2019-2025
25 companies · $457 in 2025
The $457 reported for 2025 was more than what 84% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $672 · 2023: $686 · 2024: $378 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.18 | 2021-2024 | |
| Shield Therapeutics INC | $258.02 | 2022-2025 | Accrufer |
| Currax Pharmaceuticals LLC | $239.01 | 2021-2024 | Contrave |
| Exeltis, USA INC. | $222.45 | 2022-2025 | Slynd |
| Astellas Pharma US INC | $193.32 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $189.86 | 2021-2025 | Zurzuvae |
| Organon LLC | $179.44 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $165.28 | 2023-2025 | |
| Aspira Women'S Health INC | $144.99 | 2022 | |
| Evofem Biosciences, INC. | $125.66 | 2021-2024 | Phexxi |
| Avion Pharmaceuticals | $113.38 | 2021-2023 | Balcoltra |
| Pfizer INC. | $111.87 | 2022-2024 | |
| Novo Nordisk INC | $55.42 | 2023-2025 | Wegovy |
| Axsome Therapeutics, INC. | $51.24 | 2022-2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $42.58 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $33.88 | 2022-2024 | Myosure Tissue Removal Device, Novasure |
| Lupin INC. | $29.72 | 2021 | |
| Millicent US INC | $29.46 | 2025 | Femlyv |
| Dexcom, INC. | $27.35 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $23.81 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $19.72 | 2022 | |
| Smith+Nephew, INC. | $18.78 | 2025 | Pico |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.14 | 2024 | |
| Merck Sharp & Dohme LLC | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Waddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.